Role of HDAC3 on p53 expression and apoptosis in T cells of patients with multiple sclerosis

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Zhang, Fanglin ^a   Shi, Yaping ^a   Wang, Lily ^a   Sriram, Subramaniam ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE 3; PROTEIN P53; TRICHOSTATIN A; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENE TARGETING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; CASE CONTROL STUDY; DNA MICROARRAY; DOSE RESPONSE; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; KINETICS; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PATHOLOGY;

ADULT; APOPTOSIS; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; KINETICS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; T-LYMPHOCYTES; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 79951571473     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016795     Document Type: Article

References (54)

1. Compston A, Coles A, (2008) Multiple sclerosis. Lancet 372: 1502-1517.
2. Frohman EM, Racke MK, Raine CS, (2006) Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 354: 942-955.
3. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG, (2000) Multiple Sclerosis. NewEngJ Med 343: 938-946.
4. Zivadinov R, Weinstock-Guttman B, Zorzon M, Uxa L, Serafin M, et al. (2009) Gene-environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis. J Neuroimmunol 209: 123-130.
5. McFarland HF, Martin R, (2007) Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 8: 913-919.
6. Deng X, Ljunggren-Rose A, Maas K, Sriram S, (2005) Defective ATM-p53-mediated apoptotic pathway in multiple sclerosis. Ann Neurol 58: 577-584.
7. Dinarello CA, Anti-inflammatory Agents: Present and Future. Cell 140: 935-950.
8. Smith BC, Denu JM, (2009) Chemical mechanisms of histone lysine and arginine modifications. Biochim Biophys Acta 1789: 45-57.
9. Ficner R, (2009) Novel structural insights into class I and II histone deacetylases. Curr Top Med Chem 9: 235-240.
10. Brandl A, Heinzel T, Kramer OH, (2009) Histone deacetylases: salesmen and customers in the post-translational modification market. Biol Cell 101: 193-205.
11. Stimson L, La Thangue NB, (2009) Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett 280: 177-183.
12. Spange S, Wagner T, Heinzel T, Kramer OH, (2009) Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 41: 185-198.
13. Kruse JP, Gu W, (2009) Modes of p53 regulation. Cell 137: 609-622.
14. Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT, (2009) Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 32: 591-601.
15. Noh EJ, Lim DS, Jeong G, Lee JS, (2009) An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcription-dependent manner. Biochem Biophys Res Commun 378: 326-331.
16. Butler R, Bates GP, (2006) Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat Rev Neurosci 7: 784-796.
17. Gregoretti IV, Lee YM, Goodson HV, (2004) Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338: 17-31.
18. Chen X, Wong P, Radany E, Wong JY, (2009) HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. Cancer Biother Radiopharm 24: 689-699.
19. Di Gennaro E, Bruzzese F, Pepe S, Leone A, Delrio P, et al. (2009) Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. Cancer Biol Ther 8: 782-791.
20. Lavin MF, Gueven N, (2006) The complexity of p53 stabilization and activation. Cell Death Differ 13: 941-950.
21. Vogelstein B, Lane D, Levine AJ, (2000) Surfing the p53 network. Nature 408: 307-310.
22. Vousden KH, Lane DP, (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8: 275-283.
23. Wang L, Zhang B, Wolfinger RD, Chen X, (2008) An integrated approach for the analysis of biological pathways using mixed models. PLoS Genet 4: e1000115.
24. Satoh J, Illes Z, Peterfalvi A, Tabunoki H, Rozsa C, et al. (2007) Aberrant transcriptional regulatory network in T cells of multiple sclerosis. Neurosci Lett 422: 30-33.
25. Goertsches RH, Hecker M, Zettl UK, (2008) Monitoring of multiple sclerosis immunotherapy: from single candidates to biomarker networks. J Neurol 255(Suppl 6): 48-57.
26. Munro KM, Perreau VM, (2009) Current and future applications of transcriptomics for discovery in CNS disease and injury. Neurosignals 17: 311-327.
27. Itoh Y, Suzuki T, Miyata N, (2008) Isoform-selective histone deacetylase inhibitors. Curr Pharm Des 14: 529-544.
28. Xu WS, Parmigiani RB, Marks PA, (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552.
29. Habold C, Poehlmann A, Bajbouj K, Hartig R, Korkmaz KS, et al. (2008) Trichostatin A causes p53 to switch oxidative-damaged colorectal cancer cells from cell cycle arrest into apoptosis. J Cell Mol Med 12: 607-621.
30. Park H, Lee YJ, Kim TH, Lee J, Yoon S, et al. (2008) Effects of trichostatin A, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells. Int J Mol Med 22: 605-611.
31. Lee EJ, Lee BB, Kim SJ, Park YD, Park J, et al. (2008) Histone deacetylase inhibitor scriptaid induces cell cycle arrest and epigenetic change in colon cancer cells. Int J Oncol 33: 767-776.
32. Spurling CC, Godman CA, Noonan EJ, Rasmussen TP, Rosenberg DW, et al. (2008) HDAC3 overexpression and colon cancer cell proliferation and differentiation. Mol Carcinog 47: 137-147.
33. Minamiya Y, Ono T, Saito H, Takahashi N, Ito M, et al. Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Tumour Biol.
34. Moreno DA, Scrideli CA, Cortez MA, de Paula Queiroz R, Valera ET, et al. Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. Br J Haematol.
35. Cecconi D, Donadelli M, Dalla Pozza E, Rinalducci S, Zolla L, et al. (2009) Synergistic effect of trichostatin A and 5-aza-2′-deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: a proteomic study. Proteomics 9: 1952-1966.
36. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, et al. (2004) Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5: 455-463.
37. Alamdari N, Smith IJ, Aversa Z, Hasselgren PO, Sepsis and glucocorticoids upregulate p300 and downregulate HDAC6 expression and activity in skeletal muscle. Am J Physiol Regul Integr Comp Physiol 299: R509-520.
38. Horiuchi M, Morinobu A, Chin T, Sakai Y, Kurosaka M, et al. (2009) Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. J Rheumatol 36: 1580-1589.
39. Camelo S, Iglesias AH, Hwang D, Due B, Ryu H, et al. (2005) Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol 164: 10-21.
40. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W, (2008) Acetylation is indispensable for p53 activation. Cell 133: 612-626.
41. Murphy ME, Leu JI, George DL, (2004) p53 moves to mitochondria: a turn on the path to apoptosis. Cell Cycle 3: 836-839.
42. Brooks CL, Gu W, (2003) Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 15: 164-171.
43. Yamaguchi H, Woods NT, Piluso LG, Lee HH, Chen J, et al. (2009) p53 acetylation is crucial for its transcription-independent proapoptotic functions. J Biol Chem 284: 11171-11183.
44. Sykes SM, Stanek TJ, Frank A, Murphy ME, McMahon SB, (2009) Acetylation of the DNA binding domain regulates transcription-independent apoptosis by p53. J Biol Chem 284: 20197-20205.
45. Vaseva AV, Moll UM, (2009) The mitochondrial p53 pathway. Biochim Biophys Acta 1787: 414-420.
46. Han J, Goldstein LA, Hou W, Gastman BR, Rabinowich H, Regulation of mitochondrial apoptotic events by p53-mediated disruption of complexes between antiapoptotic Bcl-2 members and Bim. J Biol Chem 285: 22473-22483.
47. Chen S, Ye J, Kijima I, Evans D, The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression. Proc Natl Acad Sci U S A 107: 11032-11037.
48. Afonso PV, Mekaouche M, Mortreux F, Toulza F, Moriceau A, et al. Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors. Blood.
49. Biran A, Brownstein M, Haklai R, Kloog Y, Downregulation of survivin and aurora a by histone deacetylase and RAS inhibitors: A new drug combination for cancer therapy. Int J Cancer.
50. Zhang F, Sriram S, (2009) Identification and characterization of the interferon-beta-mediated p53 signal pathway in human peripheral blood mononuclear cells. Immunology 128: e905-918.
51. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
52. Reimers M, Carey VJ, (2006) Bioconductor: an open source framework for bioinformatics and computational biology. Methods Enzymol 411: 119-134.
53. Wang L, Chen X, Wolfinger RD, Franklin JL, Coffey RJ, et al. (2009) A unified mixed effects model for gene set analysis of time course microarray experiments. Stat Appl Genet Mol Biol 8: Article 47.
54. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I, (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125: 279-284.